The FDA is relaxing some time-based deferrals for donating blood; new guidance aims to streamline the COVID-19 vaccination process; Congress has been called on to solidify cannabidiol (CBD) regulations.
After years of pressure from blood banks, the American Medical Association, and LGBTQ rights organizations, the FDA plans on easing restrictions on gay and bisexual men from donating blood, according to The Washington Post. This new guidance will base blood donation eligibility on gender-inclusive, individual risk-assessment questions rather than time-based deferrals, with the effect that gay men are no longer banned from donating blood for extensive periods of time; in 1985, the ban was a lifetime one, and this was shortened to 1 year in 2015 before being reduced again to 3 months at the start of the COVID-19 pandemic.
Yesterday, a committee of FDA advisors voted unanimously for a simplified COVID-19 vaccination strategy, according to NPR. The new rule would treat COVID-19 vaccines as interchangeable, in that regardless of the manufacturer, all vaccines (first dose or booster) would have the same formulation and target the same viral strain or strains. An additional consideration proposed, but not voted on, would include an annual COVID-19 vaccination schedule, much like the flu vaccine.
Yesterday, the FDA announced that it is calling on Congress to establish guidance on cannabidiol (CBD) products and other hemp products, such as delta-8 tetrahydrocannabinol, according to STAT. This decision came after nearly 4 years, as the FDA struggled to find a solution that would allow CBD to be legally sold in capsules, gummy form, and other foods, while also being considered a prescription drug. With the use of CBD products raising various health concerns, especially with long-term use, a new regulation on CBD may benefit consumers by providing risk management measures, such as clear labels, prevention of contaminants, CBD content limits, and a minimum purchase age.
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
August 13th 2025More than 8 in 10 patients with rheumatoid arthritis were taking 5 or more medications at once, a practice linked to older age, multiple comorbidities, and more than 2000 potential drug-to-drug interactions.
Read More